Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SOLIGENIX, INC. (SNGX)

Soligenix adds $2.5 million to at-the-market stock sale program with Rodman & Renshaw

Neutral Impact 2 of 5 financing Written later

Soligenix filed a prospectus supplement on June 26, 2026, raising the maximum aggregate offering amount under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,500,000. The company previously sold approximately $6,234,000 of shares under prior supplements covering up to $6,406,000. The filing makes additional shares available for sale, which could add to the number of outstanding shares and dilute existing shareholders.

Key points

  • Maximum offering under the Sales Agreement increased by an additional $2,500,000 via a prospectus supplement filed June 26, 2026
  • Previously sold approximately $6,234,000 of common stock under prior supplements covering up to $6,406,000
  • Sales Agreement dated January 23, 2026, with Rodman & Renshaw LLC; legal opinion filed as Exhibit 5.1

The filing

CompanySOLIGENIX, INC. (SNGX)
Form8-K, current report
Filed with the SECJun 26, 2026, 4:06 PM ET
Accession number0001104659-26-078251

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.